Cannabix Technologies Provides Update For imme

Cannabix Technologies Provides Update
For immediate release. Vancouver, British Columbia, June 1, 2015:Cannabix Technologies Inc.(CSE: BLO, OTC PINK: BLOZF) (the “Company”) developer of a hand-held Cannabix marijuana breathalyzer for law enforcement and the workplace, is pleased to provide the following development update:

Cannabix has been using a methodical iterative product development process to develop its marijuana breathalyzer. Using this method, the product is developed in prototype stages with each stage used to advance the product to subsequent stages. Cannabix has moved the development of the Cannabix marijuana breathalyzer from a very early concept stage through the proof of concept stage and to the Alpha prototype stage.

The current iteration of the Alpha prototype is primarily used for testing purposes to help establish key features and define the direction of future component iterations by eliminating unnecessary features and design aspects early in the process. The Alpha version of the Cannabix breathalyzer utilizes spit separation technology to avoid contamination of THC breath samples collected for analysis. The Company continues to refine the sensitivity and modify certain components in its efforts to be able to achieve medical grade reproducibility of test results. To date, the Company has progressed well in testing with medical marijuana users and is working to advance the product to a Beta prototype stage as soon as developments permit. The Alpha prototype is not intended for third party testing.

The Company continues to define specifications required from suppliers to be incorporated into a Beta version of the Cannabix breathalyzer. Only a Beta version will be acceptable for third party testing to assess the operability and measurement precision of the device for use by law enforcement.

To date, the Company has advanced development of this ground breaking technology in an efficient and accountable manner. The Company continues to maintain its development transparency, reporting each milestone as it has been achieved.

Kal Malhi, President of Cannabix Technologies stated, “I am proud of the manner in which we have taken an academic concept on breath testing for THC to our current Alpha prototype stage. We have achieved this development in a very fiscally responsible manner and have been accountable to our shareholders along each step of the way. I, my partners, family members and colleagues continue to hold approximately 1/3rd of the equity in the Company. In addition, we have very loyal shareholders who have further supported us financially through exercise of warrants as we have achieved milestones. Cannabix is well funded to achieve its objectives and is progressing steadily and continues to engage some of the best minds in the field to develop this technology for law enforcement and the workplace.”

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Neither CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Contact
For additional information on Cannabix Technologies Inc. please visit our website at http://www.cannabixtechnologies.com or email info@cannabixtechnologies.com